Dihydrotanshinone I Attenuates Atherosclerosis via Inhibiting NLRP3 Inflammasome Activation and Modulating Gut Microbiota
Authors:
Open Access
- 23 July 2026
- journal article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 49 (7) , 1140-1152
Abstract
Atherosclerosis (AS), a primary contributor to cardiovascular disease, is driven by hyperlipidemia, chronic inflammation, and gut dysbiosis. Although Salvia miltiorrhiza Bunge (Danshen) has long been used to treat atherosclerotic disorders, its most potent anti-inflammatory constituent remains unclear. Screening 12 constituents from Danshen revealed that dihydrotanshinone I (DHT) was the most potent inhibitor of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation in vitro. In an atherosclerotic mouse model, DHT treatment effectively attenuated dyslipidemia and reduced atherosclerotic plaque burden in the aorta and aortic sinus. Mechanistically, DHT significantly downregulated the aortic mRNA expression of key inflammasome components (NLRP3, ASC, Caspase-1, and IL-1β) and significantly suppressed the aortic protein levels of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). Furthermore, gut microbiota analysis indicated that DHT alleviated high-fat diet-induced gut dysbiosis by restoring gut microbial diversity. This was characterized by a decrease in pathobionts (Rikenellaceae_RC9_gut_group, Muribaculum, and [Eubacterium]_ventriosum_group) and an increase in beneficial genera (Akkermansia and Allobaculum). Fecal microbiota transplantation (FMT) confirmed that these atheroprotective effects were transferable via the gut microbiota, highlighting the key role of microbial modulation. Collectively, DHT exerts its anti-atherosclerotic effects by simultaneously improving lipid metabolism, inhibiting NLRP3 inflammasome activation, and restoring gut microbial homeostasis.Keywords
This publication has 56 references indexed in Scilit:
- Medications for Lipid Control: Statins vs Newer DrugsCanadian Journal of Cardiology, 2024
- Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative ReviewCardiology and Therapy, 2024
- Short-chain fatty acids (SCFAs) from gastrointestinal disorders, metabolism, epigenetics, central nervous system to cancer - A mini-reviewChemico-Biological Interactions, 2023
- Salvia miltiorrhiza and Tanshinone IIA reduce endothelial inflammation and atherosclerotic plaque formation through inhibiting COX-2Biomedicine & Pharmacotherapy, 2023
- Atherosclerosis: Recent developmentsCell, 2022
- Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseasesActa Pharmaceutica Sinica B, 2021
- Dietary Pterostilbene and Resveratrol Modulate the Gut Microbiota Influenced by Circadian Rhythm DysregulationMolecular Nutrition & Food Research, 2021
- Investigation of gut microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencingBiomedicine & Pharmacotherapy, 2020
- Diversity of Bacteria Exhibiting Bile Acid-inducible 7α-dehydroxylation Genes in the Human GutComputational and Structural Biotechnology Journal, 2019
- Cryptotanshinone inhibits TNF-α-induced early atherogenic events in vitroThe Journal of Physiological Sciences, 2016